Hope, Evidence, and Hard Questions in Duchenne Muscular Dystrophy
I’ve been reflecting on the disappointing outcomes and the reaction to Sarepta Therapeutics’ recently announced clinical trial results for its Duchenne muscular dystrophy treatments, AMONDYS